Emma Walmsley – Talk Bio

GSK Trims Pipeline and Upgrades Guidance in Emma Walmsley’s Last Earnings Report

4 weeks ago talkbio0Tagged dividend, earnings, Emma Walmsley, guidance upgrade, Medical Specialities, operating profit, pipeline reduction, R&D, SmithKline Beecham

GSK; pipeline reduction; earnings; Emma Walmsley; Q3 2025; guidance upgrade; Specialty Medicines; operating profit; dividend; R&D progress

GSK Appoints Luke Miels as New CEO, Succeeding Emma Walmsley on Jan. 1, 2026

2 months ago talkbio0Tagged Appointments, CEO, Emma Walmsley, Leadership Transition, Luke Miels, R&D pipeline, SmithKline Beecham, specialty medicines, Vaccines

GSK; Luke Miels; Emma Walmsley; CEO appointment; pharmaceuticals; leadership transition; specialty medicines; vaccines; R&D pipeline

GSK CEO Emma Walmsley Steps Down After 9 Years; Luke Miels to Succeed

2 months ago talkbio0Tagged CEO, Drug Industry, Emma Walmsley, Haleon demerger, Leadership Change, Luke Miels, SmithKline Beecham, specialty medicines, Succession planning, Transition Mutation, Vaccines

Emma Walmsley; GSK; CEO transition; Luke Miels; leadership change; pharmaceutical industry; Haleon demerger; specialty medicines; vaccines; succession planning